With tucatinib, a new orally available, highly selective and reversible HER2-targeting small-molecule tyrosine kinase inhibitor is on the horizon with promising anti-tumor activity in gastric cancer xenograft models and CRC cancer if combined with trastuzumab [106,107]. Here, ERBB2 is linked to neoplasm.